“Our SNPsig assays are the same high level of accuracy as our PCR SARS-CoV-2 portfolio,” Mullis said. More variants will be added as they are identified.
“primary challenge for COVID-19 diagnostics companies is ensuring their products continue to accurately test for the virus, regardless of the variant, and to innovate at the challenging pace required to remain clinically relevant"
“to keep track of new SARS-CoV-2 variants in real time as they arise & , as a result, continue to analyze our assays to ensure they remain able to detect the virus with the same high level of accuracy"
#Novacyt "SNPsig assays provide an alternative to next generation sequencing & S gene target failure (SGTF), enabling scientists to analyse & monitor relevant genomic mutations on site, within a matter of hours" #ALNOV#NCYT
Sales - £28m > £30m (Yourgene £18>£20m)
Cash - 🤔
COVID prods on sale - 3🤔
Market Cap - £761m
There's a margin of error to account for BBI accounts which aren't public, awaiting GeneDrive which reports 31/03, Avacta account were published 23/01 last yr.
Say £5m tops. Small fry when you consider imbalance of collective market capitalisations.